<![CDATA[Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal]]>
Merck & Co., Inc. (MRK) Dividend Stock Analysis
Linked here is a detailed quantitative analysis of Merck &amp; Co., Inc.&nbsp;(MRK). Below are some highlights from the above linked analysis: Company Description:&nbs...
<![CDATA[Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion ]]>
<![CDATA[Lonza to Acquire Five U.S. CDMO Sites From Merck KGaA]]>
<![CDATA[Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch]]>
Merck to boost next decade revenue forecast on new drugs optimism
PCSK9 Pill - When Will Merck Start The Hiring Process ?
PCSK9 Pill - When Will Merck Start The Hiring Process ? Anonymous (not verified) Thu, 10/29/2026 - 16:22 field_thread_url https://cafepharma.com/boards/thr...
The Merck/Moderna Results
The Merck/Moderna Results Anonymous (not verified) Fri, 10/23/2026 - 13:17 pharmagather item url The Merck/Moderna Results pharmagather...
Merck reveals study success, and possible safety worries, for eye drug hopeful
A medicine acquired in a $1.3 billion buyout came through in the first of two pivotal studies in diabetic macular edema, though language regarding the drug’s safety stirred debate...
<![CDATA[argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities ]]>
<![CDATA[M&A Roundup: Johnson & Johnson Acquires Ollin Biosciences, Eli Lilly Acquires Calytrix Bio, AmyriAD...
Merck Pays $400M for Cancer Drug Prospect From China-Based SciBrunch
Merck now has global rights to a SciBrunch Therapeutics drug candidate designed to block mutated versions of the cancer-driving protein KRAS G12D. This class of targeted cancer the...
Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer
The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and...
Drug Approval Marks Another Win for Merck KGaA’s Rare Tumor Strategy
Merck KGaA drug Pimjetmi is now FDA approved for treating tenosynovial giant cell tumor. This drug complements other rare tumor assets the Germany-based drugmaker has acquired in a...
Merck Commits $2.9 Billion to Pennsylvania Vaccine and Drug Sites
Merck plans a $2.9 billion Pennsylvania expansion through 2030, including $550 million for West Point and Spring House research facilities.
<![CDATA[Novo Terminates Research Collaboration With Korro Bio ]]>
Merck KGaA bets on RNAi with $1.3B Silence buyout
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
Lonza buys its way to a bigger US drug manufacturing network
Lonza has agreed to buy 5 US manufacturing sites from Merck KGaA, adding about 1,100 employees and capacity for cancer drug components and gene therapy vectors as drug production m...
<![CDATA[InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly]]>
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ended a seven-year run and two startups secured venture...
Merck’s new BioReliance® Facility in Darmstadt: supporting biologics development and commercialization in Europe
Merck’s new BioReliance® Facility in Darmstadt, Germany, will support biologics testing, GMP release testing and stability studies in Europe. The post Merck’s new BioReliance® Faci...
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.